Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy

Abstract

⁴The aim of this study was to evaluate changes in lipid profiles in patients with type 2 diabetes after treatment conversion from rosiglitazone to pioglitazone while maintaining stable statin and other lipid-altering therapies.

A total of 305 patients were enrolled in this open-label study. Patients had been taking stable dosages of rosiglitazone and statins for > 90 days. At baseline, patients discontinued rosiglitazone and started pioglitazone 30 mg/day, but continued statins and other lipid-altering therapies. The primary end point was change from baseline in fasting triglyceride levels.

At 17 weeks after treatment conversion, patients had significant reductions in triglycerides (-15.2%), total cholesterol (-9.0%), and low-density lipoprotein (LDL) particle concentration (-189 nmol/L), and increases in LDL cholesterol (+2.2%), high-density lipoprotein (HDL) cholesterol (+1.8%), and LDL particle diameter (+0.23 nm). In conclusion, after treatment conversion from rosiglitazone to pioglitazone while maintaining stable statin therapy, patients with type 2 diabetes had marked improvements in lipid profiles along with stable glycaemic control.

Keywords

lipids apolipoproteins LDL particles statins type 2 diabetes thiazolidinediones

References

1. Haffner SM. Management of dyslipidemia in adults with diabetes. Diabetes Care 2003;26(suppl 1):S83–S86.

2. Geiss LS , Herman WH , Smith PJ for the National Diabetes Data Group . Mortality in non-insulin-dependent diabetes. 2nd ed. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health. Diabetes in America, 2005.

3. Koskinen P , Manttari M , Manninen V , Huttunen JK , Heinonen OP , Frick MH. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992;15:820–5.

4. Turner RC , Millns H , Neil HA et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS 23). BMJ 1998;316:823–8.

5. Mykkanen L , Laakso M , Penttila I , Pyorala K. Asymptomatic hyperglycemia and cardiovascular risk factors in the elderly. Atherosclerosis 1991;88:153–61.

6. Haffner SM. Dyslipidemia management in adults with diabetes. Diabetes Care 2004;27(suppl 1):S68–S71.

7. Hokanson JE , Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996;3:213–19.

8. Blake GJ , Otvos JD , Rifai N , Ridker PM. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation 2002;106:1930–7.

9. St Pierre AC , Cantin B , Dagenais GR et al. Low-density lipoprotein sub-fractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol 2005;25:553–9.

10.

10. Jeppesen J , Hein HO , Suadicani P , Gyntelberg F. Relation of high TG-low HDL cholesterol and LDL cholesterol to the incidence of ischemic heart disease. An 8-year follow-up in the Copenhagen Male Study. Arterioscler Thromb Vasc Biol 1997;17:1114–20.

11.

11. Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care 2004;27:1496–504.

12.

12. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106–18.

13.

13. Perez A , Khan M , Johnson T , Karunaratne M. Pioglitazone plus a sulphonylurea or metformin is associated with increased lipoprotein particle size in patients with type 2 diabetes. Diabetes Vasc Dis Res 2004;1:44–50.

14.

14. Gegick CG , Altheimer MD. Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice. Endocr Pract 2001;7:162–9.

15.

15. King AB. A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones. Diabetes Care 2000;23:557.

16.

16. LaCivita KA , Villareal G. Differences in lipid profiles of patients given rosiglitazone followed by pioglitazone. Curr Med Res Opin 2002;18:363–70.

17.

17. Khan MA , St Peter JV , Xue JL. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 2002;25:708–11.

18.

18. Goldberg RB , Kendall DM , Deeg MA et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005;28:1547–54.

19.

19. Lamarche B , Tchernof A , Moorjani S et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation 1997;95:69–75.

20.

20. Miller BD , Alderman EL , Haskell WL , Fair JM , Krauss RM. Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project. Circulation 1996;94:2146–53.

21.

21. Ruotolo G , Ericsson CG , Tettamanti C et al. Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). J Am Coll Cardiol 1998;32:1648–56.

22.

22. McNamara JR , Jenner JL , Li Z , Wilson PW , Schaefer EJ. Change in LDL particle size is associated with change in plasma triglyceride concentration. Arterioscler Thromb 1992;12:1284–90.

23.

23. Austin MA , King MC , Vranizan KM , Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990;82:495–506.

24.

24. Lamarche B , Moorjani S , Lupien PJ et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec cardiovascular study. Circulation 1996;94:273–8.

25.

25. Syvanne M , Ahola M , Lahdenpera S et al. High density lipoprotein sub-fractions in non-insulin-dependent diabetes mellitus and coronary artery disease. J Lipid Res 1995;36:573–82.

26.

26. Witte DR , Taskinen MR , Perttunen-Nio H , van Tol A , Livingstone S , Calhoun HM. Study of agreement between LDL size as measured by nuclear magnetic resonance and gradient gel electrophoresis. J Lipid Res 2004;45:1069–76.

27.

27. Dormandy JA , Charbonnel B , Eckland DJA et al. on behalf of the PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitazone Clinical Trial In macrovascular Events): a randomised controlled trial. Lancet 2005;366:1279–89.